Page 110 - 《中国药房》2021年23期
P. 110

[13]  IBN SAIED W,MERCERON S,SCHWEBEL C,et al.           with levofloxacin[J]. Pediatrics,2014,134(1):e146-e153.
             Ventilator-associated pneumonia due to Stenotrophomo-  [28]  PATEL K,GOLDMAN J L. Safety concerns surrounding
             nas maltophilia:risk factors and outcome[J]. J Infect,  quinolone use in children[J]. J Clin Pharmacol,2016,56
             2020,80(3):279-285.                                (9):1060-1075.
        [14]  HOTTA G,MATSUMURA Y,KATO K,et al. Risk fac-   [29]  胡亚美,江载芳.诸福棠实用儿科学[M]. 7 版.北京:人民
             tors and outcomes of Stenotrophomonas maltophilia bacte-  卫生出版社,2010:874-892.
             raemia:a comparison with bacteraemia caused by Pseudo-  [30]  JAMES E F. Martindale:the extra pharmacopoeia[M].
             monas aeruginosa and Acinetobacter species[J]. PLoS  31st edition. London:Royal Pharmaceutical Society,
             One,2014,9(11):e112208.                             2000:129-298.
        [15]  胡付品,郭燕,朱德妹,等. 2020 年 CHINET 中国细菌耐             [31]  TANDAN M,CORMICAN M,VELLINGA A. Adverse
             药监测[J].中国感染与化疗杂志,2021,21(4):377-387.                events of fluoroquinolones vs. other antimicrobials pre-
        [16]  HANG Y T,LIN C Y,CHEN Y H,et al. Update on infec-  scribed in primary care:a systematic review and me-
             tions caused by Stenotrophomonas maltophilia with parti-  ta-analysis of randomized controlled trials[J]. Int J Antimi-
             cular attention to resistance mechanisms and therapeutic  crob Agents,2018,52(5):529-540.
             options[J]. Front Microbiol,2015,2(6):893.     [32]  COUTINHO A E,CHAPMAN K E. The anti-inflammatory
        [17]  KO J H,KANG C I,CORNEJO-JUÁREZ P E T,et al.        and immunosuppressive effects of glucocorticoids,recent
             Fluoroquinolones versus trimethoprim-sulfamethoxazole  developments and mechanistic insights[J]. Mol Cell Endo-
             for the treatment of Stenotrophomonas maltophilia infec-  crinol,2011,335(1):2-13.
             tions:a systematic review and meta-analysis[J]. Clin  [33]  TÉBLICK A,PEETERS B,LANGOUCHE L,et al. Adre-
             Microbiol Infect,2019,25(5):546-554.                nal function and dysfunction in critically ill patients[J].
        [18]  CHIEN S,WELLS T G,BLUMER J L,et al. Levofloxa-     Nat Rev Endocrinol,2019,15(7):417-427.
             cin pharmacokinetics in children[J]. J Clin Pharmacol,  [34]  ANNANE D. Corticosteroids for severe sepsis:an evi-
             2005,45(2):153-160.                                 dence-based guide for physicians[J]. Ann Intensive Care,
        [19]  ZHOU L,BAO J,MA J. Hemolytic anemia and reactive   2011,1(1):7.
             thrombocytosis associated with cefoperazone/sulbactam[J].  [35]  WEISS S L,FITZGERALD J C,PAPPACHAN J,et al.
             Front Pharmacol,2019,10:1342.                       Global epidemiology of pediatric severe sepsis:the sepsis
        [20]  REN X,LIU D,DING N,et al. Safety evaluation of cepha-  prevalence,outcomes,and therapies study[J]. Am J Respir
             losporins based on utilization and adverse drug events:  Crit Care Med,2015,191(10):1147-1157.
             analysis of two databases in China[J]. Expert Opin Drug  [36]  EL-NAWAWY A,KHATER D,Omar H,et al. Evaluation
             Saf,2012,11(5):689-697.                             of early corticosteroid therapy in management of pediatric
        [21]  谢悦良,贾素洁,刘晶晶,等.治疗药物监测在头孢哌酮钠                         septic shock in pediatric intensive care patients:a rando-
             舒巴坦致脑病诊疗中的应用[J].中国新药与临床杂志,                          mized clinical study[J]. Pediatr Infect Dis J,2017,36(2):
             2019,38(6):378-381.                                 155-159.
        [22]  李燕,孙冲,吕萌,等.头孢哌酮钠舒巴坦钠的儿童药品不                    [37]  ZIMMERMAN J J. Adjunctive steroid therapy for treat-
             良反应分析[J/OL].中国药物警戒,2021(2021-06-28)                 ment of pediatric septic shock[J]. Pediatr Clin North Am,
              [2021-07-11]. http://kns.cnki.net/kcms/detail/11.5219.R.  2017,64(5):1133-1146.
              20210628.1556.004.html.                       [38]  ROCHWERG B,OCZKOWSKI S J,SIEMIENIUK R A C,
        [23]  BEUMIER M,CASU G S,HITES M,et al. Elevated β-      et al. Corticosteroids in sepsis:an updated systematic
             lactam concentrations associated with neurological deterio-  review and meta-analysis[J]. Crit Care Med,2018,46(9):
             ration in ICU septic patients[J]. Minerva Anestesiol,2015,  1411-1420.
             81(5):497-506.                                 [39]  RHODES A,EVANS L E,ALHAZZANI W,et al. Survi-
        [24]  FUGATE J E,KALIMULLAH E A,HOCKER S E,et al.        ving sepsis campaign:international guidelines for manage-
             Cefepime neurotoxicity in the intensive care unit:a cause  ment of sepsis and septic shock:2016[J]. Intensive Care
             of severe,underappreciated encephalopathy[J]. Crit Care,  Med,2017,43(3):304-377.
             2013,17(6):264.                                [40]  LAVIOLLE B,ANNANE D,FOUGEROU C,et al. Gluco
        [25]  BHATTACHARYYA S,DARBY R R,RAIBAGKAR P,             and mineralocorticoid biological effects of a 7-day treat-
             et al. Antibiotic-associated encephalopathy[J]. Neurology,  ment with low doses of hydrocortisone and fludrocorti-
             2016,86(10):963-971.                                sone in septic shock[J]. Intensive Care Med,2012,38(8):
        [26]  孔钦翔,张照如,李家斌.抗菌药物相关性脑病研究进                           1306-1314.
             展[J].中国抗生素杂志,2017,42(7):621-625.                             (收稿日期:2021-04-06  修回日期:2021-09-07)
        [27]  BRADLEY J S,KAUFFMAN R E,BALIS D A,et al. As-                                      (编辑:刘明伟)
             sessment of musculoskeletal toxicity 5 years after therapy


        ·2916 ·  China Pharmacy 2021 Vol. 32 No. 23                                 中国药房    2021年第32卷第23期
   105   106   107   108   109   110   111   112   113   114   115